Retracted: Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray as a Prerequisite for Broad Clinical Applications (A Study From the Lunenburg Lymphoma Biomarker Consortium)

Journal of Clinical Pathology - United Kingdom
doi 10.1136/jcp.2008.057257
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

miR‑150 Is a Negative Independent Prognostic Biomarker for Primary Gastrointestinal Diffuse Large B‑cell Lymphoma

Oncology Letters
Cancer ResearchOncology
2020English

FDG-PET as a Biomarker for Early Response in Diffuse Large B-Cell Lymphoma as Well as in Hodgkin Lymphoma? Ready for Implementation in Clinical Practice?

Haematologica
Hematology
2016English

Diffuse Large B-Cell Lymphoma

2020English

Diffuse Large B-Cell Lymphoma Presenting as a Cardiac Mass

Texas Heart Institute Journal
MedicineCardiovascular MedicineCardiology
2016English

Diffuse Large B-Cell Lymphoma: A Case Report

Clinical and Experimental Health Sciences
2018English

The Graft-Versus-Lymphoma Effect in Diffuse Large B-Cell Lymphoma

Biology of Blood and Marrow Transplantation
TransplantationHematology
2015English

Secondary Cutaneous Diffuse Large B-Cell Lymphoma Has a Higher International Prognostic Index Score and Worse Prognosis Than Diffuse Large B-Cell Lymphoma, Leg Type

Acta Dermato-Venereologica
DermatologyMedicine
2016English

Prognostic Significance of CD44 Expression in Diffuse Large B Cell Lymphoma of Activated and Germinal Centre B Cell-Like Types: A Tissue Microarray Analysis of 90 Cases

Journal of Clinical Pathology
MedicineForensic MedicinePathology
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy